1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

CMS Payment Experiment Strains Legal Powers, Reimbursement Norms

 
• By Cathy Kelly

'Perverse' new payment model for Part B drugs may test the limits of its innovation center’s waiver authority and has already drawn lawsuit threat.

The Medicare Part B payment model being planned by the Centers for Medicare and Medicaid Services has drawn threats of legal and congressional action even in its current state as a proposed rule, demonstrating the strength of the opposition against it.

Announced by the agency March 8, the payment model for Part B drugs is envisioned as a large-scale initiative that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Price Inflation Rebates: Biden Policies Add Teeth To Trump’s Pharma Tariff Threat

 
• By Cathy Kelly

Companies with significant exposure to Medicare and Medicaid have fewer options for passing along higher costs to consumers because of price controls in the programs.

US FDA Acting Drug Center Chief Corrigan-Curay Retiring, Senior Staff Remake Continues

 
• By Derrick Gingery

The news coincides with rumors that Commissioner Martin Makary soon will name a new Center for Drug Evaluation and Research director.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.